|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR inhibitors including both monoclonal antibodies (cetuximab and panitumumab) and tyrosine kinase inhibitors (erlotinib, gefitinib and dasatinib) have been used in clinical trials for the treatment of advanced cSCC, achieving only partial clinical benefit.
|
31747091 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the absence of prospective randomized phase 3 trials to evaluate and compare the efficacy and safety of chemotherapeutics, epidermal growth factor receptor (EGFR) inhibitors and anti-PD-1 antibodies, no final recommendation for systemic therapy can be given for patients with locally advanced or metastatic cSCC.
|
31833610 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment for metastatic cSCC was poorly characterized and restricted to the use of chemotherapy and epidermal growth factor receptor inhibitors.
|
31833609 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other treatments, such as epidermal growth factor receptor inhibitors have also been used in the treatment of cSCC with moderate success.
|
31394558 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) inhibitors and, more recently, immune checkpoint blockers (ICBs) showed activity in R/M sSCC.
|
31112973 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma.
|
30683916 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The development of cutaneous squamous cell carcinoma (cSCC) is associated with activation of the epidermal growth factor receptor (EGFR).
|
31289508 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa.
|
31796084 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This was supported by the high expression of EGFR in CSCC clinical samples.
|
31638204 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the role of LINC00520 in the development of cSCC via EGFR and phosphoinositide 3-kinase-protein kinase B (PI3K/Akt) signaling pathways.
|
30707166 |
2019 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a phase 2 trial to determine the response rate to therapy with erlotinib, an EGFR tyrosine kinase inhibitor, in patients with locoregionally recurrent or metastatic CSCC that was not amenable to curative treatment (NCT01198028).
|
29579331 |
2018 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma.
|
28978917 |
2017 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC.
|
28243326 |
2017 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the role of EGFR as a prognostic factor in CSCC.
|
27510450 |
2017 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKA showed EGFR and MYC anomalies at an incidence intermediate between CKA and SCC.
|
23521519 |
2013 |
|
Squamous cell carcinoma of skin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This action of T-cad in SCC may serve as a paradigm explaining other malignancies displaying concomitant T-cad loss and enhanced EGFR activity.
|
22592160 |
2012 |
|
Squamous cell carcinoma of skin
|
0.100 |
Biomarker
|
disease |
BEFREE |
In view of the 18% complete response rate we observed, EGFR tyrosine kinase inhibitors should be further explored in the treatment of aggressive CSCC.
|
22261807 |
2012 |
|
Squamous cell carcinoma of skin
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While in other tumors, especially lung cancer and glioblastoma, the EGFR mutations are frequent genetic events, it is unknown whether EGFR is mutated or amplified in SCC of the skin and what would be its pathogenic role in this malignancy and its precursors.
|
21531084 |
2011 |
|
Squamous cell carcinoma of skin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells.
|
14708611 |
2003 |
|
Squamous cell carcinoma of skin
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that the clone with EGFR expression might selectively metastasize in some cutaneous SCCs.
|
11385224 |
2001 |